---
schema_version: "secwatch.filing_event.v1"
accession: "0000872589-25-000026"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:05:34.226137+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q3'25: Revenue $3.75B (+1%), GAAP EPS $13.62, Non-GAAP EPS $11.83; EYLEA sales down 28%

## Summary
- Total revenue $3.754B (+1% YoY); GAAP EPS $13.62 (+18%), non-GAAP EPS $11.83 (-5%).
- Dupixent global net sales (Sanofi) up 27% to $4.86B; total EYLEA HD+EYLEA U.S. down 28% to $1.11B.
- FDA approved Libtayo for adjuvant CSCC; positive Phase 3 data for cemdisiran in myasthenia gravis and DB-OTO gene therapy in hearing loss.
- 2025 guidance revised: GAAP R&D $5.68-5.75B, GAAP SG&A $2.775-2.845B, gross margin about 82%, ETR about 14%.

## SEC filing metadata
- accession: 0000872589-25-000026
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/0000872589-25-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/regn-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000872589-25-000026
- JSON: https://secwatch.observer/filing/0000872589-25-000026.json
- Plain text: https://secwatch.observer/filing/0000872589-25-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.